HYPE3 logo

Hypera Stock Price

Symbol: BOVESPA:HYPE3Market Cap: R$16.4bCategory: Pharmaceuticals & Biotech

HYPE3 Share Price Performance

R$25.88
-3.17 (-10.91%)
26.1% undervalued intrinsic discount
R$35.00
Fair Value
R$25.88
-3.17 (-10.91%)
26.1% undervalued intrinsic discount
R$35.00
Fair Value
Price R$25.88
AnalystHighTarget R$35.00
AnalystConsensusTarget R$28.84
AnalystLowTarget R$22.00

HYPE3 Community Narratives

AN
AnalystHighTarget
AnalystHighTarget·Updated
Fair Value R$35.00 26.1% undervalued intrinsic discount

Aging Population And Rising Middle Class Will Drive Healthcare Expansion

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value R$28.84 10.3% undervalued intrinsic discount

Working Capital Optimization And Neosaldina Launches Will Shape Future Operations

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget·Updated
Fair Value R$22.00 17.6% overvalued intrinsic discount

Brazil Pricing Pressures And Aging Workforce Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

HYPE3 Community Fair Values

Recent HYPE3 News & Updates

No updates

Hypera S.A. Key Details

R$6.7b

Revenue

R$2.9b

Cost of Revenue

R$3.8b

Gross Profit

R$3.0b

Other Expenses

R$810.6m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 06, 2025
Earnings per share (EPS)
1.28
Gross Margin
56.39%
Net Profit Margin
12.10%
Debt/Equity Ratio
79.3%

Hypera S.A. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About HYPE3

Founded
1999
Employees
10481
CEO
Breno Pires de Oliveira
WebsiteView website
www.hypera.com.br

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex – A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Brazilian Market Performance

  • 7 Days: -0.9%
  • 3 Months: -3.1%
  • 1 Year: -2.0%
  • Year to Date: 6.2%
Over the last 7 days, the market has remained flat, although notably the Consumer Staples sector declined by 6.2%. In line with that, the market has also been flat over the past year. As for the next few years, earnings are expected to grow by 14% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading